Pfizer Inc. PFE today announced randomized Phase 2 data that showed PD-0332991
(PD-991) in combination with letrozole significantly extended progression free
survival (PFS) compared with letrozole alone in post-menopausal patients with
estrogen receptor positive (ER+), human epidermal growth factor receptor 2
negative (HER2-) locally advanced or metastatic breast cancer. For patients
treated with the combination of PD-991 plus letrozole, median PFS was 26.1
months, a statistically significant improvement compared to the median PFS in
women who received letrozole alone, which was 7.5 months (HR=0.37 [95% CI:
0.21, 0.63]; P <0.001). These data were presented today and featured in a
press conference at the 35^th Annual San Antonio Breast Cancer Symposium
(Abstract #S1-6).
Breast cancer is the most commonly diagnosed cancer^1 and the leading cause of
cancer death among women worldwide.^2 Estrogen receptor positive, HER2- breast
cancer represents approximately 60 percent of all cases of breast cancer.^3
Despite currently available treatments, survival rates for advanced or
metastatic breast cancer remain low.^4
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in